Digital Library
Close Browse articles from a journal
     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             43 results found
no title author magazine year volume issue page(s) type
1 ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial † Mounier, N.

25 8 p. 1622-1628
article
2 Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study Buzzoni, R.

25 8 p. 1597-1603
article
3 Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies Turati, F.

25 8 p. 1526-1535
article
4 A phase I study of cabozantinib (XL184) in patients with renal cell cancer Choueiri, T.K.

25 8 p. 1603-1608
article
5 Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients Ali, H.R.

25 8 p. 1536-1543
article
6 Carboplatin's fourth decade: still searching for its sweet spot Quinn, D.I.

25 8 p. 1457-1458
article
7 Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research Grover, P.K.

25 8 p. 1506-1516
article
8 Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor De Cecco, L.

25 8 p. 1628-1635
article
9 Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO) Zardavas, D.

25 8 p. 1558-1562
article
10 Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck Misiukiewicz, K.

25 8 p. 1667-1668
article
11 Corrections to “Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer”
25 8 p. 1672
article
12 Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force Aapro, M.

25 8 p. 1492-1499
article
13 Early-stage lung cancer—what do the experts recommend? Leighl, N.B.

25 8 p. 1451-1453
article
14 Editorial Board
25 8 p. ii-iii
article
15 ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas Wilhelm, M.

25 8 p. 1500-1505
article
16 European cancer mortality predictions for the year 2014 Malvezzi, M.

25 8 p. 1650-1656
article
17 Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression † Nitz, U.

25 8 p. 1551-1557
article
18 ‘Fracture incidence after 3 years of aromatase inhibitor therapy’ Laurent, M.R.

25 8 p. 1665-1666
article
19 Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors Goldstein, D.

25 8 p. 1643-1649
article
20 Immunoscoring breast cancer: TILs remember what they target Curigliano, G.

25 8 p. 1455-1456
article
21 Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact Nabholtz, J.M.

25 8 p. 1570-1577
article
22 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up Vansteenkiste, J.

25 8 p. 1462-1474
article
23 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease Besse, B.

25 8 p. 1475-1484
article
24 Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors Balmaña, J.

25 8 p. 1656-1663
article
25 Plasma methionine, choline, betaine, and dimethylglycine in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Nitter, M.

25 8 p. 1609-1615
article
26 ‘Pre-cachexia’: a non-existing phenomenon in cancer? Blauwhoff-Buskermolen, S.

25 8 p. 1668-1669
article
27 Quality assurance in the treatment of colorectal cancer: the EURECCA initiative Breugom, A.J.

25 8 p. 1485-1492
article
28 Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer Mok, T.S.

25 8 p. 1578-1584
article
29 RE: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma Diwakar, D.

25 8 p. 1670-1671
article
30 Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort Cathomas, R.

25 8 p. 1591-1597
article
31 Reply to the letter to the editor ‘Fracture incidence after 3 years of aromatase inhibitor therapy’ by Laurent et al. Bouvard, B.

25 8 p. 1666-1667
article
32 Risks of the new EU Data protection regulation: an ESMO position paper endorsed by the European oncology community Casali, P.G.

25 8 p. 1458-1461
article
33 Should we use the angiotensin-converting enzyme inhibitors for the treatment of anti-VEGF-induced hypertension? Emile, G.

25 8 p. 1669-1670
article
34 Smoking and survival of colorectal cancer patients: systematic review and meta-analysis Walter, V.

25 8 p. 1517-1525
article
35 SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib Zhang, L.

25 8 p. 1584-1590
article
36 Table of Contents
25 8 p. iv-vi
article
37 The dilemmas of breast cancer treatment and increased fracture risk Malik, L.

25 8 p. 1664
article
38 ‘The dilemmas of breast cancer treatment and increased fracture risk’ by Malik Bouvard, B.

25 8 p. 1664-1665
article
39 The immunogenicity of breast cancer—molecular subtypes matter Denkert, C.

25 8 p. 1453-1455
article
40 Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial Kramar, A.

25 8 p. 1563-1570
article
41 Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial Loi, S.

25 8 p. 1544-1550
article
42 Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial † Glynne-Jones, R.

25 8 p. 1616-1622
article
43 Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model—a study based on data from an international multicentre project (EPCRC-CSA) Blum, D.

25 8 p. 1635-1642
article
                             43 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands